Physician profile
Fernando Sanchez
NPI 1598863813
$1,003.52
in general payments reported to CMS, 2019-2025
11 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $36.51 · 2022: $40.50 · 2023: $101 · 2024: $354 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $301.96 | 2019-2023 | Rezzayo, Kimyrsa, Vabomere |
| Gilead Sciences, INC. | $175.13 | 2024-2025 | |
| Viiv Healthcare Company | $154.72 | 2025 | Cabenuva, Dovato |
| Shionogi INC | $114.09 | 2024-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $68.30 | 2024-2025 | Pifeltro, Delstrigo, Isentress |
| Abbvie INC. | $55.61 | 2023-2025 | Dalvance |
| Alexion Pharmaceuticals, INC. | $40.50 | 2022 | |
| Astellas Pharma US INC | $28.59 | 2024 | Cresemba |
| Mimedx Group, INC. | $23.59 | 2024 | |
| Supernus Pharmaceuticals, INC. | $23.46 | 2019 | |
| Insmed, INC. | $17.57 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.